Adaptimmune Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Adaptimmune Therapeutics's past years’ income statements indicate that its last revenue has increased compared to the previous period by 122% to $60,281,000. The net income raised on -$113,871,000 and profit margin reached -189%. Total operating expenses were $200,022,000.
Profit Margin
| 2014 | 604.62K | -12.70M | -2100.85% |
|---|---|---|---|
| 2015 | 10.72M | -21.58M | -201.36% |
| 2016 | 14.19M | -71.57M | -504.15% |
| 2017 | 37.83M | -70.13M | -185.39% |
| 2018 | 59.50M | -95.51M | -160.51% |
| 2019 | 1.12M | -137.16M | -12225.04% |
| 2020 | 3.95M | -130.09M | -3286.81% |
| 2021 | 6.14M | -158.09M | -2570.99% |
| 2022 | 27.14M | -165.45M | -609.46% |
| 2023 | 60.28M | -113.87M | -188.9% |
ADAP Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 60.28M | 27.14M | 6.14M | 3.95M | 1.12M | 59.50M | 37.83M | 14.19M | 10.72M | 604.62K |
Cost of revenue | 9.85M | 127.72M | 111.09M | 91.56M | 97.50M | 0 | 0 | 0 | 0 | 0 |
Gross profit | 50.42M | -100.57M | -104.94M | -87.61M | -96.37M | 59.50M | 37.83M | 14.19M | 10.72M | 604.62K |
Operating exp. | ||||||||||
Research and development | 126.50M | 127.72M | 111.09M | 91.56M | 97.50M | 98.26M | 87.38M | 63.78M | 23.19M | 12.52M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 200.02M | 191.11M | 168.39M | 137.36M | 140.89M | 141.87M | 118.49M | 86.99M | 33.78M | 14.97M |
Operating income | -138.03M | -163.96M | -162.24M | -133.40M | -139.77M | -82.36M | -80.66M | -72.79M | -23.06M | -14.37M |
Other income (expenses), net | 25.50M | 1.00M | 4.94M | 3.47M | 2.84M | -15.50M | 10.97M | 1.00M | -3.19M | 2.82M |
Income before tax | -112.53M | -162.95M | -157.29M | -129.93M | -136.92M | -95.01M | -69.68M | -70.68M | -23.69M | -14.37M |
Income tax expense | 1.33M | 2.49M | 791K | 162K | 242K | 497K | 451K | 892K | -2.10M | -1.67M |
Net income | -113.87M | -165.45M | -158.09M | -130.09M | -137.16M | -95.51M | -70.13M | -71.57M | -21.58M | -12.70M |
Earnings per share | ||||||||||
Basic EPS | -0.57 | -1.03 | -1.01 | -0.91 | -1.31 | -0.98 | -0.8 | -1.01 | -0.6 | -0.02 |
Diluted EPS | -0.57 | -1.03 | -1.01 | -0.91 | -1.31 | -0.98 | -0.8 | -1.01 | -0.6 | -0.02 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |